Muir-Torre syndrome
Muir-Torre Syndrome (MTS) is a subtype of Lynch syndrome. It is an inherited condition that increases a person’s lifetime risk for developing rare types of skin, colorectal, and genitourinary tract cancers.
The facts
- Muir-Torre Syndrome (MTS) is an inherited disorder sometimes found in people with colorectal cancer.
- As with Lynch syndrome, MTS is caused by an inherited harmful change (mutation) in one of the DNA mismatch repair (MMR) genes.
- The mutation is passed from one generation to the next, and in a family with a parent who has an inherited change in their DNA, each child has 50% of being diagnosed with MTS.
The MLH1 and MSH2 genes are most commonly mutated in MTS patients.
![female researcher using microscope](/sites/default/files/styles/fifty_fifty/public/media/images/female_researcher_microscope_close.jpg.webp?itok=rpjLwv2I)
Skin cancer and MTS
The presence of specific types of skin or internal cancers are the primary symptoms of MTS.
Skin Cancers
- Sebaceous adenoma is the most frequent symptom in people with MTS (80-99%).
- Sebaceous carcinoma of the eyelid is an aggressive cancer that spreads to the eye orbit and can be fatal.
- Additional skin cancers include sebaceous epitheliomas and keratoacanthomas.
![young person caring for an older individual](/sites/default/files/styles/fifty_fifty/public/media/images/two_generations_hugging.jpg.webp?itok=VskSPQTY)
Internal cancers
- 30-79% of MTS patients have colon cancer or stomach cancer.
- 5-29% of MTS patients have endometrial (uterine) or breast cancer.
- About 60% of people with MTS develop metastatic disease.
![cell under microscope](/sites/default/files/styles/fifty_fifty/public/media/images/cells_under_microscope_purple.jpg.webp?itok=e65w85x4)
Diagnosis and risks
Since MTS is a subtype of Lynch syndrome, the diagnosis, risk factors, and treatment of this disorder is very similar.
Looking for some support?
My BlueHQTop resources
![A sign at the BMS headquarters](/sites/default/files/styles/450x250/public/media/images/bms-sign-1920.png.webp?itok=qtRzhXHJ)
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
![The city of Philadelphia](/sites/default/files/styles/450x250/public/media/images/philadelphia.png.webp?itok=CyT8nkqx)
Alliance adds partners to expand 45+ Reasons campaign
The Alliance’s 45+ Reasons campaign is part of the Cycles of Impact initiative launched and supported by Independence Blue Cross in 2022 to address the urgent public health issue of colorectal cancer among the Black population.
![Pillars in front of a court building](/sites/default/files/styles/450x250/public/media/images/court-pillars_0.png.webp?itok=vjw6DOGa)
Appeals Court decision protects access to no-cost preventive CRC screening
The U.S. Court of Appeals for the Fifth Circuit reversed a district court decision that had ruled provisions in the Affordable Care Act (ACA), which provide for no-cost preventive screening for colorectal cancer and other conditions, unconstitutional.